Page 21 - 2019年8月第30卷第16期
P. 21

基于协同度的山西省医药产业创新政策研究                                                  Δ


               *
                               #
        裴中阳 ,胡安霞,闫娟娟 ,王 源(山西中医药大学健康服务与管理学院,山西 晋中 030619)
        中图分类号 R95           文献标志码 A          文章编号     1001-0408(2019)16-2176-05
        DOI   10.6039/j.issn.1001-0408.2019.16.04

        摘   要   目的:为山西省医药产业创新政策的制定提供科学依据,以加快推进山西省医药产业创新发展。方法:收集山西省
        2003-2018 年期间医药产业创新相关政策,对其政策效力、政策措施和政策目标进行量化,分析政策效力变化及其协同度。结
        果:2003-2018年,山西省医药产业创新政策总体效力呈增加趋势,但平均效力增幅不明显。各项政策中运用最多的措施是行政
        措施和人事措施,这2项措施之间的协同度最高,而金融措施与其他措施之间的协同度在2013年后逐渐降低,财政税收措施与其
        他各类措施的协同度均较低;各项政策目标间的协同水平差异较大,自主创新与其他目标之间的协同度较高,而科技成果转化、知
        识产权保护、技术引进扩散这3项目标与其他目标之间的协同度较低。结论:山西省应加强医药产业创新政策的战略性研究和系
        统性规划,加强对各项措施及力度支持的综合研究,注重强化各种措施间的协同性,适当增加对金融措施的利用,同时强化科技成
        果转化、知识产权保护、技术引进扩散等相关政策目标的制定,并出台相关配套政策,使各项政策协同发挥作用。
        关键词 医药产业;创新政策;协同度;山西省

        Study on Innovation Policies of Pharmaceutical Industry in Shanxi Province Based on Synergy
        PEI Zhongyang,HU Anxia,YAN Juanjuan,WANG Yuan(School of Health Service and Management,Shanxi
        University of TCM,Shanxi Jinzhong 030619,China)

        ABSTRACT    OBJECTIVE:To provide scientific basis for the formulation of innovation policy in pharmaceutical industry and to
        accelerate the development of pharmaceutical industry innovation in Shanxi province. METHODS: The related policies of
        pharmaceutical industry innovation in Shanxi province from 2003 to 2018 were collected,then the policy effectiveness,measures
        and objectives were quantified to analyze the evolution of policy effectiveness and the synergy degree between policy measures and
        objectives. RESULTS: During 2003-2018, overall effectiveness of innovation policies in pharmaceutical industry in Shanxi
        province showed an increasing trend,but the average effectiveness did not increase significantly. The most used measures in
        policies were administrative and personnel measures,which had the highest degree of synergy;while the degree of synergy
        between financial measures and other measures had gradually decreased after 2013;the synergy between fiscal and tax measures
        and other measures was the lowest. The synergies between the goals varied greatly,the synergies between independent innovation
        and other objectives were higher,and three objectives as transformation of scientific and technological achievements,intellectual
        property protection and technology introduction and diffusion synergized with other objectives were poorly. CONCLUSIONS:
        Shanxi province should strengthen strategic research and systematic planning of innovation policies in the pharmaceutical industry;
        strengthen comprehensive research on various measures and strong support;pay attention to strengthening the synergies among
        various measures,and appropriately increase the use of financial measures. Also,the formulation of relevant policy goals such as
        the transformation of scientific and technological achievements, the protection of intellectual property rights, technology
        introduction and diffusion should be strengthened,and supporting policies should be formulated to enable various policies to play a
        coordinated role.
        KEYWORDS     Pharmaceutical industry;Innovation policies;Synergy;Shanxi province



            2018 年,我国对全球医药研发的贡献率已上升至                        规模小、科研投入低、高附加值品种缺乏、管理机制滞
                                               [1]
        4%~8%,已经跨入全球医药创新第二梯队 。改革开                           后、发展环境欠佳,当地医药产业的创新发展程度与其
        放以来,“长三角”、“珠三角”和“环渤海”地区依靠区域                         他先进地区相比仍有很大的差距 。
                                                                                        [3]
        优势,逐渐形成了制药企业集聚地,创新发展速度快 。                               提升医药产业创新能力的一个关键因素,就在于政
                                                      [2]
        而山西省地处内陆地区,自主创新能力不足,医药产业                            策支持。随着国家对医药健康产业的重视,山西省也相

            Δ 基金项目:山西省软科学研究项目(No.2016042011-2);山西省          继出台了各类政策支持以引导医药产业的创新发展。
        高等学校人文社会科学重点研究基地项目(No.2017338);山西中医药                笔者在调研中发现,山西省关于医药产业创新发展的政
        大学科技创新能力培育计划项目(No.2018PY-044)                       策文件数量繁多,但是如果这些政策之间不能互相配
            *讲师,硕士。研究方向:药事管理。电话:0351-3179915。E-
                                                            合、协同作用,将不利于政策发挥预期作用,并且还会影
        mail:pzy_1234567@163.com
            # 通信作者:副教授,博士。研究方向:药事管理。电话:0351-                响各方利益相关者准确把握和应用政策。因此,亟需加
        3179920。E-mail:yanjuanjuan79@163.com                强对山西省医药产业创新政策体系的研究,以便更好地


        ·2176  ·  China Pharmacy 2019 Vol. 30 No. 16                                中国药房    2019年第30卷第16期
   16   17   18   19   20   21   22   23   24   25   26